붙임 1 **2023 OPEN INNOVATION PLAZA 기술 신청 양식**

기술(파이프라인) 명

<기본 정보>

신청유형	■ 네트워크(파트너링) □ 기술사업화・투자촉진경진대회
분류	□ target ■ 후보물질 □ 기반기술 □ 기타( )
물질 분류	□ Small molecule □ 천연물 □ 단백질 ■ 유전자 ■ 세포 □ 기타( )
적응증	■ 항암 □ 면역 □ 대사성질환 □ 심혈관질환 □ 호흡기질환 □ 신경계질환 □ 안과질환 □ 감염성질환 □ 신장 및 비뇨계질환 □ 소아질환 □ 기타( )
개발단계	□ Target □ Hit □ Lead □ Lead Optimization □ GLP Toxicity ■ 초기 임상(P1/2a) □ 후기 임상(P2b/3)
제안유형	□ 공동 연구 ■ 공동 개발 □ 공동 판매 ■ 라이센싱 □ 투자 □ 합작투자회사 설립 □ 기타( )
기술요약	A candidate for blood cancer CAR-T cell therapy targeting the protein CD19

<기술 정보>

국내 특허	1. 10-2136063 (□ 출원 전 □ 출원 ■ 등록) 2. (□ 출원 전 □ 출원 □ 등록) 그 외 ( ) 건
해외 특허 여부 및 번호	■ 있음 □ 없음 1. US 11,534,462 B1 2. JP 7089806 B2 3. CN ZL201880079137.7 4. CA 3083936 외 유럽, 호주 심사 중
연구개발 상황	□ 종료 ■ 진행 중 □ 기타( )
유효성 자료 여부	■ 있음(□ in vitro □ in vivo) □ 없음
안전성 자료 여부	■ 있음(□ in vitro □ in vivo) □ 없음

<연구자 정보 및 기술관련 문의처>

연구자 기관명	앱클론 ㈜	연구자명	
기술 담당자명	김종훈	담당자 연락처 및 이메일	02-2109-1366 jhkim@abclon.com

<기술 정보>

기업 개요	◯ AbClon is a public biotech based in Seoul, South Korea and listed in KOSDAQ (a Korea Exchange). AbClon was established in 2010 as a joint venture by Korean scientists with innovative antibody technology and Swedish scientists with advanced biotechnology to develop antibody drugs. The platforms of the company are the proprietary antibody discovery, CAR-T (Chimeric Antigen Receptor-T) therapeutics, and bi-specific antibody development ◯ NEST: new epitope screening technology to find novel antibody with novel epitope ◯ Autologous CAR-T: T cells are collected from the patients by the process called leukapheresis then the isolated T cells are engineered ex vivo by transduction of new genetic materials, activation and expansion, then those cells returns to the patients to kill the cancer cells ◯ "switchable" CAR-T: control of CAR-T activity and persistence by switch molecule ◯ AffiMab: bi-specific antibody platform with genetic fusion of an Affibody molecule and mAb. Affibody molecule is antibody like protein scaffold with size of only 6.5kd having fully functional antibody. AffiMab retain symetric structure and close to canonical IgG. This gives you bi-specific, bi-valency, and longer half-life with stable structure and production
기술 개요	◯ AT101: a candidate for blood cancer CAR-T cell therapy targeting the protein CD19 ◯ Differently from the currently available CAR-T cell therapies, AT101 employed a novel antibody called h1218. AT101 showed a unique MOA (mechanism of action) for binding to antigen on tumor cell and killing the tumor cell. The dose-escalation Phase I study showed 91.7% ORR (Overall response rate) and 75% CR (complete response). Moreover, at middle and upper dose levels, the best CR was 100%. ◯ AbClon is pursuing an opportunity to out-license or collaborate AT101.
미팅 희망 기업	